Stocks

For Marijuana Stocks in 2017, Real Estate Is the Next Big Catalyst

For Marijuana Stocks in 2017, Real Estate Is the Next Big Catalyst

For Marijuana Stocks in 2017, Real Estate Is the Next Big Catalyst

Real estate is the next big catalyst for marijuana stocks in 2017, as more voters demand legalized recreational and medical cannabis in their states.

Top Marijuana Stocks to Watch in 2017

Top Marijuana Stocks to Watch in 2017

Sales in the legal marijuana industry are skyrocketing, which is why Money Morning created a list of the top marijuana stocks to watch in 2017. But because marijuana is still illegal under federal law, and many of the marijuana stocks on the market are so volatile, this isn’t a list of recommendations. Rather, it’s a list of marijuana stocks they are watching closely in 2017.

Canadian marijuana stocks regain momentum after Christmas

Canadian Marijuana Stocks Regain Momentum After Christmas

In the last few months, the medical marijuana growers have dominated the trading activity on the TSX Venture in terms of dollar volume almost exclusively, belying a persistent interest from investors in Canada and the United States.

Canopy Growth: What to Do Now That the Hype Has Settled Down

Canopy Growth: What to Do Now That the Hype Has Settled Down

Canopy, previously listed on the Canadian Venture Exchange under stock symbol TWD (Tweed was the original company, later consolidated into Canopy), began trading publicly on the Toronto Stock Exchange in July amid great anticipation from investors and financial markets.

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.

Is 2017 a Do-Or-Die Year for Aurora Cannabis Stock?

Is 2017 a Do-Or-Die Year for Aurora Cannabis Stock?

The fed’s report was largely positive for the recreational marijuana industry when it was released Tuesday. Aurora Cannabis stock was one of the biggest pot stock beneficiaries of the announcement, but has since had a regression in share price.

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

According to a report by the equity research firm Cowen & Co., marijuana will generate $50 billion in revenue by 2026. That’s roughly eight times the estimated revenue this year. GW Pharmaceuticals and Insys Therapeutics are two big companies with an even bigger future.

Investors Hoping To Ride High On Trailblazing Marijuana Company

Investors Hoping to Ride High on Trailblazing Marijuana Company

With several states passing measures to legalize marijuana in 2016, the cannabis business looks poised to finally to take off. But for investors, there remains a quandary: How do you find a way to get in on the ground floor of this new growth industry?

Quarterly Snapshot of Kaya Holdings

Quarterly Snapshot of Kaya Holdings

On Nov. 21, 2016, Kaya Holdings (OTCQB:KAYS), whose subsidiary Kaya Shack opened its first cannabis dispensary in Portland, Oregon, in 2014, announced that it had filed its third quarterly report of 2016, reporting a 700% year-over-year revenue increase.

Cannabis Company Files to List on the New York Stock Exchange

Cannabis Company Files to List on the New York Stock Exchange

New Cannabis Ventures broke the news Monday evening. It will be the first publicly-traded cannabis-related Real Estate Investor Trust or REIT and, if approved, would be the first cannabis company to be traded at the venerable NYSE.

GWPH Riding High: Stock Rises on Clinical Trial's Positive Results

GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results

On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.

MassRoots Neglects to Mention Default on Debt in Letter to Shareholders

MassRoots Neglects to Mention Default on Debt in Letter to Shareholders

On Sept. 26, 2016, Massroots (OTCQB:MSRT) issued a letter from Isaac Dietrich, Chairman and Chief Executive Officer, on the company’s outlook for Fall 2016, including updates on the product pipeline, user growth and expense reductions, among others; however, the letter failed to address the company’s recent default on debt.

Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches - Sources

Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches – Sources

GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.

SEC Charges 'King Of Pot' With Investment Fraud

SEC Charges ‘King Of Pot’ With Investment Fraud

Federal securities regulators have filed a complaint against Bruce Perlowin that charges the CEO of publicly-traded Hemp Inc of committing a long-running fraud by evading securities registration provisions and selling hundreds of millions of unregistered shares.

SEC

SEC Temporarily Suspends Securities Trading of Pineapple Express

On April 28, 2016, the U.S. Securities and Exchange Commission announced the temporary suspension of trading in Pineapple Express (OTC: PNPL) due to unusual market activity in the company’s securities. The suspension started at 9:30 a.m. EDT today and will end at 11:59 p.m. EDT on May 11.

GW Pharma

GW Pharma Reports Positive Results and Stock More than Doubles by Mid-Day

On March 14, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for the first pivotal Phase 3 study of Epidiolex, a CBD-based medicine, in treating Dravet syndrome, a severe form of pediatric epilepsy.

Capital Markets

Making CBD, and the Capital Markets, Bioavailable

Chris Bunka, the CEO and Chair at Lexaria Corp. (CSE: LXX) (OTCQB: LXRP), suspects that market-makers and broker-dealers are engaged in something potentially illegal and certainly untoward in connection with the stock of the company.

NASDAQ

Massroots Inches Closer to NASDAQ Listing

While there has been a significant victory in Oregon to open up delivery services and challenges to the status quo are taking place in banking, the most promising development for everyday investors is the ongoing effort to open up the public markets to marijuana firms.

SEC Rules

Cannabusiness Experts Expect SEC Rules Will Matter … Given Time

Randy Shipley, the founder and CEO of CannaFundr.com, is among those who believe that the new SEC rules will “potentially” have a positive influence on the marijuana industry.

Zynerba

Zynerba: The Need for Speculative Fortitude

Zynerba presented the status of its research program at BIO Investor Forum. This is a 14-year-old annual biotech gathering, with roughly 600 attendees from 21 countries, and the presentation, in San Francisco, looked likely to be a big event in this company’s development.

Zynerba IPO

Zynerba IPO a Big $275 Million Entry for Cannabinoids

It has been a bit of a dry spell for decent IPOs in the cannabis space. But the rains have come down with the initial public offering of Devon, Pennsylvania-based Zynerba Pharmaceuticals (NASDAQ: ZYNE).

stock

SEC Settles Charges in 2014 Marijuana Stock Scam

On July 9, 2015, the Securities and Exchange Commission announced that it had settled charges against Alexander Hawatmeh and Christopher Mrowca. So far, so good, but is the legal marijuana industry any safer for investors?

market

Are Cannabis Stocks Riding a Market Wave?

In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.

MassRoots

Fascinating Case Study Begins April 9 as MassRoots Goes Public

MassRoots, which will begin trading on or around April 9, 2015, under the ticker MSRT, is set to be the first public cannabis company with a revenue model and a customer acquisition strategy built entirely around social media platforms.


Page 1 of 512345
Top